Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Decreased by Private Advisor Group LLC

Private Advisor Group LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 39.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,510 shares of the biopharmaceutical company's stock after selling 36,175 shares during the period. Private Advisor Group LLC's holdings in Gilead Sciences were worth $4,416,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Wealthcare Advisory Partners LLC grew its stake in shares of Gilead Sciences by 3.5% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 14,095 shares of the biopharmaceutical company's stock worth $1,142,000 after acquiring an additional 477 shares in the last quarter. MeadowBrook Investment Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $94,000. Gallacher Capital Management LLC boosted its position in Gilead Sciences by 28.4% in the fourth quarter. Gallacher Capital Management LLC now owns 5,585 shares of the biopharmaceutical company's stock worth $452,000 after purchasing an additional 1,237 shares during the last quarter. Sheets Smith Wealth Management raised its stake in shares of Gilead Sciences by 85.2% during the 4th quarter. Sheets Smith Wealth Management now owns 42,701 shares of the biopharmaceutical company's stock worth $3,459,000 after purchasing an additional 19,641 shares during the period. Finally, Avidian Wealth Solutions LLC grew its position in Gilead Sciences by 3.3% during the fourth quarter. Avidian Wealth Solutions LLC now owns 8,148 shares of the biopharmaceutical company's stock valued at $660,000 after buying an additional 259 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on GILD. TD Cowen decreased their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Friday, April 26th. Barclays cut their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an "equal weight" rating for the company in a research report on Monday, April 29th. Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 7th. HSBC upgraded shares of Gilead Sciences from a "reduce" rating to a "hold" rating and set a $69.00 price objective for the company in a research note on Wednesday, April 24th. Finally, Oppenheimer restated an "outperform" rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $83.69.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now directly owns 96,304 shares of the company's stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Trading Up 2.1 %

GILD stock traded up $1.38 during trading on Friday, hitting $65.96. 8,732,850 shares of the company traded hands, compared to its average volume of 7,536,398. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The company has a 50-day moving average of $69.94 and a 200-day moving average of $75.45. The firm has a market capitalization of $82.13 billion, a PE ratio of 183.22, a P/E/G ratio of 1.33 and a beta of 0.22. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts' expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $1.37 earnings per share. Analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.67%. Gilead Sciences's dividend payout ratio is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.